Navigation Links
Oxygen Biotherapeutics, Inc. Files Cosmetic Product Ingredient Statement for new Oxycyte-based Cosmetic Gel

COSTA MESA, Calif., May 1 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has filed a Cosmetic Product Ingredient Statement (CPIS) with the FDA for Dermacyte(TM) Gel, its new Oxycyte(R)-based cosmetic product. Oxycyte is the company's perfluorocarbon (PFC) therapeutic oxygen carrier.

"This voluntary filing with the FDA is a sign that we are a big step closer to bringing our first product to market," said Chris Stern, chairman and CEO of Oxygen Biotherapeutics. "This new gel, which we've named Dermacyte, is an oxygen-rich formulation of Oxycyte which we believe will promote skin health and other desirable cosmetic benefits when applied to the skin. Our gel shows amazing effects and it is just a foundation for us to morph gradually into more complex and clinical environments. It has achieved excellent test results in cytotoxicity, bacteriostasis, fungistasis, sterility and skin irritations studies. As subsequent steps, we intend to file Investigational New Drug applications with the FDA for over-the-counter drug applications both in the wound and acne sectors and go on with clinical trials as warranted."

A CPIS is a voluntary registration with the FDA recommended for a cosmetic product's commercial introduction. The acne product will be called Acnecyte(TM), and the wound product Wundecyte(TM).

"This gel is just the base of what I believe can become an extensive product line that will lead us deep into the topical sector," said Joe Tai, the newly-appointed director of Oxygen Biotherapeutics' topical division. "I dare to say that the market has not yet seen such a product."

Said Stern, "This marks another milestone in our company's development. We are now ready to shore up our efforts to enter into distribution license agreements with potential partners and emerge from a research company to a commercial enterprise."

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes. More information is available at

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by Oxygen Biotherapeutics, Inc. that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include those referring to plans and expectations for use of Dermacyte(TM) Gel in over-the counter cosmetic applications and other indications, Wundecyte(TM) in wound care, Acnecyte(TM) in acne as well as statements regarding distribution license agreements. Actual events or results may differ from Oxygen Biotherapeutics, Inc.'s expectations. There can be no assurance that the company will be able to license or partner Dermacyte Gel, Wundecyte, Acnecyte, or Oxycyte for any indications or that such licensees will generate profits for the company. Nor can there be any assurance that any Oxycyte-based products will reach the market. Additional information concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.'s business can be found in the company's public periodic filings with the Securities and Exchange Commission, which are available via Oxygen Biotherapeutics, Inc. disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
2. More than 10,000 Medicare Patients in Montana Could Be Hit by Proposed Cuts to Home Oxygen Therapy; Access to Power Wheelchairs Would Also Decrease
3. Earths Oxygen May Have Arrived Earlier
4. San Diegos SeQual Technologies Loans 35 Portable Oxygen Units to Evacuees at Qualcomm Stadium
5. CQRC Statement on the NY Times Article on Medicares Home Oxygen Benefit
6. Statement from American Association for Homecare on New York Times Article about Home Oxygen Therapy
7. Link between chronic kidney disease and oxygen-deprived tissue
8. FOXO factor promotes survival of oxygen-deprived cancer cells
9. Infants with birthmarks received less oxygen in womb
10. OxySure(R) Systems, Inc. Named to 2008 Worlds Best Technologies (WBT) List For its Unique, Safe and Easy to Use Portable Emergency Oxygen Generator, Which Provides Medical Oxygen Without the Need for Compressed Tanks
11. Home Oxygen Care Leaders Say Presidents Budget Will Lead to Significant Patient Service Disruptions, Call for Thoughtful Reforms as Opposed to Repeated Cuts
Post Your Comments:
(Date:11/28/2015)... ... November 28, 2015 , ... Beginning November 30th at 6:00 a.m. EST until 11:59 ... savings. , With possible savings of up to 20% off orders $80 or more to ... the website every few hours. , As a competitive e-commerce website for skin care and ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... According ... at the recent 2015 American Dental Association meeting in Washington D.C. revolved around the ... protect a patient’s overall health. The talk stressed the link between periodontal disease (more ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed ... As people age, more care is needed, especially with Alzheimer’s, dementia and other ... are being overworked. The forgotten part of this equation: 80 percent of medical ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I was traveling, ... from Hillside, N.J. "Many people catch diseases simply from sitting on such dirty ... be protected from germs." , He developed the patent-pending QUDRATECS to eliminate the ...
(Date:11/27/2015)... ... ... ProSidebar: Fashion is a set of 30 kinetic edge graphics ... editors can easily add an informative sidebar to any FCPX production. Create lists, ... self-animating drop zones, lines, bars, and text with the ease of FCPX's drag and ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
Breaking Medicine Technology: